The RET/PTC fusion group had more aggressive tendencies (extrathyroidal extension, lymph node metastasis, and diffuse sclerosing variant) and was classified as intermediate risk of recurrence as per the 2015 American Thyroid Association Guidelines for Differentiated Thyroid Cancer. This evidence concerns the gene RET and metastatic malignant neoplasm in the lymph nodes.